Drug Profile
MEDI 4166
Alternative Names: MEDI4166Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator MedImmune
- Class Antihyperglycaemics; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Glucagon like peptide 1 receptor agonists; PCSK9 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cardiovascular disorders; Type 2 diabetes mellitus
Most Recent Events
- 28 Dec 2018 Pharmacokinetics, pharmacodynamics, immunogenicity and adverse event data from a phase I trial in Type 2 diabetes mellitus released by MedImmune
- 01 Oct 2018 Efficacy and adverse events data from a phase II trial in Type-2 diabetes presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD-2018)
- 11 Sep 2017 Adverse events data from a phase I trial in Type-2 diabetes mellitus presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD-2017)